Investment Rating - The report suggests a positive outlook for the company, indicating that it is significantly undervalued with a market capitalization of only 2.7 billion HKD, and recommends active monitoring of the stock [9]. Core Insights - The company achieved a total revenue of 0.29 billion RMB for the fiscal year 2025, representing a year-on-year growth of 1344.77%, while net losses narrowed by 43.27% to 1.05 billion RMB [1]. - Cost control measures have been effective, with administrative expenses reduced by 16.4 million RMB and R&D costs optimized, particularly focusing on the SM17 clinical trials [2]. - The clinical development of SM17 is progressing rapidly, with promising results in the 1b phase study for atopic dermatitis, showing a 91.7% itch relief rate and 75% achieving skin lesion recovery [3]. - The company is building a differentiated pipeline in autoimmune diseases, with potential for significant business development (BD) opportunities as clinical trials advance [4]. Summary by Sections Financial Performance - Total revenue for 2025 reached 0.29 billion RMB, a substantial increase of 1344.77% year-on-year, while net losses decreased to 1.05 billion RMB, a reduction of 43.27% compared to the previous year [1]. Cost Management - The company has effectively controlled costs, reducing administrative expenses by 16.4 million RMB and optimizing R&D costs, particularly in the SM17 clinical program [2]. Clinical Development - SM17 is advancing quickly in clinical trials, with a 2nd phase study for atopic dermatitis expected to start in mid-2026, and positive results from the 1b phase study indicating high efficacy and safety compared to existing treatments [3]. Pipeline and Strategic Focus - The company is focused on developing first-in-class (FIC) and best-in-class (BIC) therapies, with a rich pipeline in autoimmune diseases and plans for significant BD opportunities as key data is released in 2026-2027 [4].

Investment Rating - The report suggests a positive outlook for the company, indicating that it is significantly undervalued with a market capitalization of only 2.7 billion HKD, and recommends active monitoring of the stock [9]. Core Insights - The company has achieved a remarkable revenue growth of 1344.77% year-on-year, reaching a total revenue of 0.29 billion RMB for the fiscal year 2025, while reducing its net loss by 43.27% to 1.05 billion RMB [1][2]. - Cost control measures have been effective, with administrative expenses reduced by 16.4 million RMB and R&D costs optimized, particularly focusing on the SM17 clinical trials [2]. - The clinical development of SM17 is progressing rapidly, with positive results from the 1b phase study for atopic dermatitis, showing a 91.7% itch relief rate and 75% achieving skin lesion recovery [3]. - The company is building a differentiated pipeline in autoimmune diseases, with a focus on first-in-class (FIC) and best-in-class (BIC) products, which are expected to lead to significant business development opportunities in 2026-2027 [4][9]. Financial Performance - The total available funds increased from 141.4 million RMB in 2024 to 351.5 million RMB, supporting the advancement of the pipeline [2]. - The company has successfully narrowed its losses from 185 million RMB in 2024 to 105 million RMB in 2025 [2]. R&D Pipeline - The company is advancing the SM17 clinical trials for atopic dermatitis and inflammatory bowel disease (IBD), with plans to submit an IND application for idiopathic pulmonary fibrosis (IPF) [3]. - The next-generation anti-CGC antibody is undergoing CMC optimization and toxicology studies, with an IND application for alopecia areata expected by Q4 2026 [7]. - A bispecific antibody targeting osteoporosis is also in development, with plans to submit an IND application by mid-2027, addressing a market with over 200 million patients globally [8].